Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-075515·CytomX Therapeutics, Inc.
Schedule 13G ownership disclosure
CytomX Therapeutics Inc
Common Stock, $0.00001 par value per share · CUSIP: 23284F105
Event date: 2025-05-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Longitude Capital Partners V, LLC
Shares: 11,538,461 · Class: 7.3%
- Longitude Venture Partners V, L.P.
Shares: 11,538,461 · Class: 7.3%
- Patrick G. Enright
Shares: 11,538,461 · Class: 7.3%
- Juliet Tammenoms Bakker
Shares: 11,538,461 · Class: 7.3%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-075515
- Form type
- SCHEDULE 13G
- Filer
- CytomX Therapeutics, Inc.
- CIK
- CIK 1501989
- Filed
- May 20, 2025
- Reporting period
- May 13, 2025
- Description
- Schedule 13G beneficial ownership